Recombinant sCD40L (Toralizumab Biosimilar) antibody
Reactivity: Human
BR, IF
Host: Mouse
Chimeric
IDEC-131
unconjugated
Recombinant Antibody
-
- Target See all sCD40L (Toralizumab Biosimilar) products
- sCD40L (Toralizumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
-
Host
- Mouse
-
Clonality
- Chimeric
-
Conjugate
- This sCD40L (Toralizumab Biosimilar) antibody is un-conjugated
- Application
- Blocking Reagent (BR), Immunofluorescence (IF)
- Purpose
- Anti-CD154 [IDEC-131 (Toralizumab)], Mouse IgG1, kappa
- Specificity
- This antibody is a non agonistic antibody specifc for human CD40 ligand.
- Characteristics
-
Original Species of Ab: Mouse
Original Format of Ab: IgG1
- Purification
- Protein A affinity purified
- Immunogen
- The original monoclonal antibody was generated by immunization with a soluble fusion protein of human gp39 (gp39-CD8).
- Clone
- IDEC-131
- Isotype
- IgG1 kappa
-
anti-sCD40L (Toralizumab Biosimilar) antibody
Reactivity: Human BR, IF Host: Rabbit Chimeric IDEC-131 unconjugated Recombinant Antibody
-
- Application Notes
- This antibody binds CD154 with an binding affinity of Kd = 5.6 nM for theoriginally characterized antibody (Brams et al., 2001)/ Phase I clinical trials of the antibody in pateints with systemic lupus ezythematoses revealed that a single intravenous infusion at doses of 0.05-15.0 mg/kg is safe and well tolerated in patients. (Davis et al., 2001). Although, no further development for this indication has been reported since the disclosure of disappointing phase II results in April 2000. In January 2001, phase II trials in psoriasis and idiopathic thrombocytopenic purpura (ITP) were initiated. By january 2002, a phase II trial in Crohn's disease was also ongoing. (Dumont FJ, 2002) Ab IDEC-131 was tested alone and in combination with rapamycin and DST for its ability to inhibit rhesus MLRs and it was seen that therapy with IDEC-131, rapamycin, and DST induced long-term allograft survival without intermittent acute rejection.(He Xu et, al., 2003) IDEC-131 was also used in a comparative study using 3 monoclonal antibodies αCD40 (2C10R4) and αCD154 (5C8H1 and IDEC-131 to check CD40/CD154 T cell costimulation pathway in a non-human primate cardiac allotransplant model (O'Neill et al., 2017) Other suitable use in ELISA, FC, IF, IP.
- Comment
-
This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
- Restrictions
- For Research Use only
-
- Concentration
- 1 mg/mL
- Buffer
- PBS with 0.02 % Proclin 300.
- Preservative
- ProClin
- Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C,-20 °C
- Storage Comment
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
- Target
- sCD40L (Toralizumab Biosimilar)
- Abstract
- sCD40L (Toralizumab Biosimilar) Products
- Target Type
- Biosimilar
- Background
- CD40L, gp39, TRAP, Tumor necrosis factor ligand superfamily member 5, TNFSF5, T-cell antigen Gp39, TNF-related activation protein, TNF-related activation protein
- UniProt
- P29965
-
You are here:
